inosine-diphosphate and Brain-Diseases

To evaluate the effectiveness of the Cytoflavin in patients with dyscirculatory encephalopathy (DE) who had a new coronavirus infection.. 82 patients were examined: 16 (19.5%) men and 66 (80.5%) women aged 58 to 80 years, mean age 69±6 years and 70±6 years, respectively. All patients had moderate vascular cognitive impairment (less than 26 points according to the MoCA test), a history of COVID-19 in the period from 3 to 12 months before the start of the study. Patients before COVID-19 were registered with a neurologist with chronic cerebrovascular diseases with non-demented cognitive impairment of vascular origin. Patients of the main group (MG) received the Cytoflavin from the 1st to the 25. It was found that during therapy with Cytoflavin, patients noted a positive trend in the form of a decrease in the symptoms of cognitive impairment, improved orientation and working memory, concentration of attention and counting. Also, patients in MG noted a decrease in fatigue and depressive disorders, an increase in motivation and a positive attitude, the emergence of interest in life, an improvement in the emotional background of mood, an increase in physical activity and working capacity. Comparing the mechanisms of development of vascular dysfunction, a pathogenetic commonality between DE and the development of consequences in the form of cognitive impairment caused by COVID-19 was noted.. Cytoflavin therapy at a dosage of 2 tablets 2 times a day for 25 days can be recommended as part of complex therapy for patients with DE and a COVID-19.. Оценить эффективность применения препарата Цитофлавин у пациентов с дисциркуляторной энцефалопатией (ДЭ), перенесших новую коронавирусную инфекцию.. Обследованы 82 пациента (16 (19,5%) мужчин и 66 (80,5%) женщин) в возрасте от 58 до 80 лет (средний — 69±6 и 70±6 лет соответственно). Все пациенты имели умеренные сосудистые когнитивные нарушения (КН, значения по Монреальской шкале оценки когнитивных функций (MoCA <26 баллов), в анамнезе — COVID-19 за 3—12 мес до начала исследования. Пациенты до заболевания COVID-19 наблюдались у невролога с хроническими цереброваскулярными заболеваниями с недементными КН. Пациенты основной группы (ОГ) получали Цитофлавин с 1-х по 25-е сутки наблюдения по 2 таблетки 2 раза в сутки на фоне стандартной базисной терапии. Пациенты группы сравнения получали только стандартную базисную терапию.. На фоне терапии Цитофлавином у пациентов ОГ отмечалась положительная динамика в виде уменьшения выраженности КН (улучшение ориентации, оперативной памяти, концентрации внимания и счета), снижение утомляемости и депрессивных нарушений, улучшение эмоционального фона настроения, повышение физической активности и работоспособности. Отмечена патогенетическая общность развития ДЭ и последствий COVID-19 в виде КН.. Применение Цитофлавина по 2 таблетки 2 раза в сутки в течение 25 сут может быть рекомендовано в составе комплексной терапии пациентам с ДЭ и перенесенным COVID-19.

Topics: Aged; Brain Diseases; COVID-19; Female; Humans; Inosine Diphosphate; Male; Middle Aged; Niacinamide

The cardiac surgery is accompanied by multifactorial alteration of the brain, which can present in different clinical types of postoperative cerebral dysfunction. A stroke was diagnosed only after coronary artery bypass graft surgery with cardiopulmonary bypass. Postoperative cognitive dysfunction (including acute cognitive dysfunction and deferred cognitive impairment) was significantly more frequent after surgery with cardiopulmonary bypass. The preoperative use of complex cytoprotective medication Cytoflavin decreased the severity of the deferred cognitive impairment. The data show the prospects of the pharmacological neuroprotection in cardiac surgery with cardiopulmonary bypass.

Topics: Aged; Brain Diseases; Cardiopulmonary Bypass; Cognitive Dissonance; Drug Combinations; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Male; Middle Aged; Neuroprotective Agents; Niacinamide; Postoperative Complications; Succinates